Businessweek

CNS Response, Inc. announced that it has received four additional patents for its PEER Interactive technology. Two of the patents, one in the U.S. and one in Japan relate to the company's method of classifying individual patients based on their unique Quantitative EEG (QEEG) responsivity profile. The third patent, issuing in Canada, relates to the company's method of determining medication efficacy by comparing QEEG data measured before and after medication administration. The fourth patent, issuing in Japan, relates to the Company's method of recommending therapy based upon an individual's unique QEEG responsivity profile. PEER Interactive correlates a reliable, well-normed neurophysiology test (QEEG) with a published physician outcome registry (PEER). A growing body of evidence -- 75 studies on PEERDossier.com -- have demonstrated reduced trial and error prescribing for physicians using QEEG. PEER studies have shown health outcomes that are two times better than treatment as usual. Mental health is an area where treatments fail frequently due to the lack of objective, physiological tests to help physicians individualize prescriptions for their patients.

CNS Response, Inc. announced that it has opened a second site for its PEER Interactive trial at Fort Belvoir Community Hospital in Virginia. Fort Belvoir is the second military site to participate under an approved, 2,000-soldier protocol and Cooperative Research and Development Agreement. PEER Interactive builds evidence for mental health treatments, an area where there has traditionally been no physiological test to help physicians individualize prescriptions for their patients, and treatments fail frequently. PEER correlates a reliable, well-normed test of brain function (EEG) with a published physician outcome registry (PEER).

CNS Response, Inc. announced that the annual meeting of stockholders of the company to be held on May 23, 2013, the shareholder is to consider and approve a resolutions to amend the company's Amended and Restated Certificate of Incorporation, as amended in order to increase the number of shares of common stock, par value $0.001 per share, authorized for issuance under the Charter from 100,000,000 to 150,000,000; and to consider other resolution to amend the company's Charter in order to create one or more new series of preferred stock, par value $0.001 per share, and authorize 15,000,000 shares of such preferred stock for issuance.

CNS Response, Inc., Annual General Meeting, May 23, 2013., at 08:00 Pacific Standard Time. Location: offices of SAIL Capital. Agenda: To elect seven directors; to amend the company's Amended and Restated Certificate of Incorporation, as amended in order to increase the number of shares of common stock; to amend the company's Charter in order to create one or more new series of preferred stock, par value $0.001 per share, and authorize 15,000,000 shares of such preferred stock for issuance; to adopt the company's 2012 Omnibus Incentive Compensation Plan, as amended, to award grants of up to an aggregate of 15,000,000 shares of common stock; to consider an advisory (non-binding) vote to approve the compensation of its named executive officers; to consider an advisory (non-binding) vote regarding the frequency of holding future say-on-pay votes; to ratify the selection by the Audit Committee of Cacciamatta Accountancy Corporation as its independent registered accounting firm for the fiscal year ending September 30, 2013; and to transact such other business.

On March 26, 2013, the Board of Directors of CNS Response, Inc. appointed its director Thomas T. Tierney to the position of Chairman of the Board.